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Reply to the Editor:
We are gratified that our experimental work in the field of
aortic graft infection1 has stimulated a critical review from an
experienced and renowned proponent of homograft vascular
reconstruction. Vascular infection occurs in the de novo setting
(ie, mycotic aneurysm, endocarditis) and after reconstruction
of the aorta or cardiac valves. In the case of aortic surgery, graft
infection of a vascular prosthesis appears to be more common
than primary mycotic aneurysm and provokes the question:
“How do these grafts get infected?” Relying on the large clin-
ical experience with cardiac valves, it is apparent that a pros-
thesis may become infected if it is placed in an infected field
or if it is exposed to a bacteremia. Postoperative bacteremia is
established as a primary cause of prosthetic valve endocarditis.
Early prosthetic valve endocarditis reflects a nosocomial bac-
teriologic pattern and occurs early after valve replacement,
before endothelialization of the prosthesis.2 In a similar fash-
ion, vascular graft infection occurs after placement in an infect-
ed field or after exposure to a bacteremia. We chose to study
the latter question, the ability of a graft to resist infection.
Reported clinical experience identifies infection of a sterile
prosthesis in a sterile field as a common clinical circum-
stance.3,4 The porcine model of graft infection, with endothe-
lial characteristics similar to those observed in human beings,
combined with an early postoperative bacteremia, was chosen
on this basis. Intraoperative bacteremia, at the doses required
to provoke graft infection, proved to be uniformly lethal in our
study. Furthermore, there is probably a direct relationship
between the ability of a graft material to resist bacteremia
before endothelialization occurs and its ability to resist estab-
lished bacteremia and infected tissues at the time of implanta-
tion. Strictly speaking, our study dealt with the resistance of
graft infection and not the treatment of infected grafts.
However, the two issues are related and remind one of the
question, “Which came first, the chicken or the egg?” Further
experimental work must be done to directly investigate de novo
native infection or vascular replacement in an infected field.
Antibiotics were not used in this study for two reasons. It
was our intent to remove as many variables as possible and in
the experimental setting to determine which graft was best in
resisting infection. Clinical series report an infinite variabili-
ty of antibiotic treatments before and after vascular graft
infection, which may confuse the results.3 Furthermore, we
suppose that most vascular graft infections occur in response
to a nosocomial bacteremia long after the perioperative
antibiotics have been discontinued, but during the vulnerable
period before endothelialization.
At present, thoracic aortic infection remains a dangerous
complication. In contrast to other cardiovascular operations,
deaths often occur after the 30-day postoperative period
because of persistent sepsis and progressive multiple organ
failure. Coselli, Cuneyt, and LeMaire4 report a current series
of thoracic aortic infections with a 30-day and hospital mor-
tality of 11% and 42%, respectively. In our article, we made a
firm distinction between the thoracic aorta and the abdominal
aorta and distal circulation. Comparisons with clinical series
in which the majority of reconstructions occur below the
diaphragm are irrelevant and were not reviewed in our manu-
script.3,5 Surgical options for the abdominal aorta are quite
different from those for the thoracic aorta. The availability of
extra-anatomic reconstruction and omental coverage and the
avoidance of extracorporeal circulation, visceral ischemia,
and embolization define the relative simplicity of abdominal
aortic surgery. Similarly, a canine model of infrarenal aortic
graft infection may not be applicable to the thoracic aorta,
despite the observation that only antibiotic-treated cryopre-
served allograft, but not untreated allograft or gelatin-sealed
polyester graft, had superior resistance to infection.6
The debate persists over which material is best to use for
reconstruction of the thoracic aorta or the cardiac valves.
Despite the intuitive notion that biologic tissue is better, the
popularity of autogenous reconstruction, and the numerous
favorable clinical series, our experimental observation has
supported the use of artificial prostheses. Further investiga-
tion will be required to provide a more comprehensive
answer.
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